Rafael Holdings, Inc. (RFL)

1.6200 0.0000 (0.00%) At close: 04:00PM EDT

Rafael Holdings, Inc.

520 Broad Street
Newark, NJ 07102
United States
212 658 1450
https://www.rafaelholdings.com

Sector(s): Real Estate
Industry: Real Estate Services
Full-time employees: 13

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Howard S. Jonas	Founder & Executive Chairman	40k	N/A	1956
Mr. William Conkling	CEO & President	751.95k	N/A	1972
Mr. David A. Polinsky Esq.	Chief Financial Officer	363.3k	N/A	1972
Ms. Barbara A. Ryan	Investor Relations Officer	N/A	N/A	1960
Mr. Gus Kodersha	Chief Technical Operations Officer	N/A	N/A	N/A
Dr. Rick Ewing	Head of Drug Discovery	N/A	N/A	N/A
Dr. John Mayer Goldberg M.D.	Chief Medical Officer	N/A	N/A	1973
Ms. Joyce J. Mason Esq.	Corporate Secretary	N/A	N/A	1959

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Corporate governance

Rafael Holdings, Inc.’s ISS governance QualityScore as of 1 May 2024 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.